Nasdaq · CIK 0001719714
MREO Mereo BioPharma Group plc
Insider trading from SEC Form 4. Last filing Feb 27, 2026.
Mereo BioPharma Group plc (MREO) has 19 SEC Form 4 filings on file from 13 insiders, the latest filed on Feb 27, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
Last 90 days
Signals
Open-market buys and sells at Mereo BioPharma Group plc, scored.
Transactions
Every row filed, 39 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | Jeremy Bender director | AGrant or award Share Options (Right to buy)derivative | +66,000 | $0.00 | $0 | 66,000 | Feb 27, 2026 |
| Feb 26, 2026 | Anders Ekblom director | AGrant or award Share Options (Right to buy)derivative | +66,000 | $0.00 | $0 | 66,000 | Feb 27, 2026 |
| Feb 26, 2026 | Pierre Jacquet director | AGrant or award Share Options (Right to buy)derivative | +66,000 | $0.00 | $0 | 66,000 | Feb 27, 2026 |
| Feb 26, 2026 | Marc J Yoskowitz director | AGrant or award Share Options (Right to buy)derivative | +66,000 | $0.00 | $0 | 66,000 | Feb 27, 2026 |
| Feb 26, 2026 | Annalisa Jenkins director | AGrant or award Share Options (Right to buy)derivative | +66,000 | $0.00 | $0 | 66,000 | Feb 27, 2026 |
| Feb 26, 2026 | Michael S Wyzga director | AGrant or award Share Options (Right to buy)derivative | +66,000 | $0.00 | $0 | 66,000 | Feb 27, 2026 |
| Feb 26, 2026 | Deepika Pakianathan director | AGrant or award Share Options (Right to buy)derivative | +66,000 | $0.00 | $0 | 66,000 | Feb 27, 2026 |
| Feb 26, 2026 | Daniel Shames director | AGrant or award Share Options (Right to buy)derivative | +66,000 | $0.00 | $0 | 66,000 | Feb 27, 2026 |
| Feb 26, 2026 | Jeremy Bender director | AGrant or award Deferred Restricted Stock Unitsderivative | +117,533 | - | - | 117,533 | Feb 27, 2026 |
| Feb 26, 2026 | Marc J Yoskowitz director | AGrant or award Deferred Restricted Stock Unitsderivative | +96,163 | - | - | 96,163 | Feb 27, 2026 |
| Feb 26, 2026 | Daniel Shames director | AGrant or award Deferred Restricted Stock Unitsderivative | +96,163 | - | - | 96,163 | Feb 27, 2026 |
| Feb 26, 2026 | Annalisa Jenkins director | AGrant or award Deferred Restricted Stock Unitsderivative | +106,848 | - | - | 106,848 | Feb 27, 2026 |
| Feb 26, 2026 | Pierre Jacquet director | AGrant or award Deferred Restricted Stock Unitsderivative | +106,848 | - | - | 106,848 | Feb 27, 2026 |
| Feb 26, 2026 | Anders Ekblom director | AGrant or award Deferred Restricted Stock Unitsderivative | +133,560 | - | - | 133,560 | Feb 27, 2026 |
| Feb 1, 2026 | Christine Ann Fox Chief Financial Officer | AGrant or award Share Options (Right to buy)derivative | +315,750 | $0.00 | $0 | 315,750 | Feb 2, 2026 |
| Feb 1, 2026 | Alexandra Hughes-Wilson See Remarks | AGrant or award Share Options (Right to buy)derivative | +183,750 | $0.00 | $0 | 183,750 | Feb 2, 2026 |
| Feb 1, 2026 | John A. Lewicki Chief Scientific Officer | AGrant or award Share Options (Right to buy)derivative | +139,913 | $0.00 | $0 | 139,913 | Feb 2, 2026 |
| Feb 1, 2026 | Denise Scots-Knight Chief Executive Officer | AGrant or award Share Options (Right to buy)derivative | +1,035,000 | $0.00 | $0 | 1,035,000 | Feb 2, 2026 |
| Feb 1, 2026 | Charles Sermon General Counsel | AGrant or award Share Options (Right to buy)derivative | +315,750 | $0.00 | $0 | 315,750 | Feb 2, 2026 |
| Feb 1, 2026 | Christine Ann Fox Chief Financial Officer | AGrant or award Share Options (Right to buy)derivative | +105,250 | $0.00 | $0 | 105,250 | Feb 2, 2026 |
| Feb 1, 2026 | Alexandra Hughes-Wilson See Remarks | AGrant or award Share Options (Right to buy)derivative | +61,250 | $0.00 | $0 | 61,250 | Feb 2, 2026 |
| Feb 1, 2026 | John A. Lewicki Chief Scientific Officer | AGrant or award Share Options (Right to buy)derivative | +46,637 | $0.00 | $0 | 46,637 | Feb 2, 2026 |
| Feb 1, 2026 | Charles Sermon General Counsel | AGrant or award Share Options (Right to buy)derivative | +105,250 | $0.00 | $0 | 105,250 | Feb 2, 2026 |
| Feb 1, 2026 | Denise Scots-Knight Chief Executive Officer | AGrant or award Share Options (Right to buy)derivative | +345,000 | $0.00 | $0 | 345,000 | Feb 2, 2026 |
| Feb 1, 2026 | Charles Sermon General Counsel | AGrant or award Share Options (Right to buy)derivative | +295,000 | $0.00 | $0 | 295,000 | Feb 2, 2026 |
| Feb 1, 2026 | Alexandra Hughes-Wilson See Remarks | AGrant or award Share Options (Right to buy)derivative | +195,000 | $0.00 | $0 | 195,000 | Feb 2, 2026 |
| Feb 1, 2026 | Denise Scots-Knight Chief Executive Officer | AGrant or award Share Options (Right to buy)derivative | +480,000 | $0.00 | $0 | 480,000 | Feb 2, 2026 |
| Feb 1, 2026 | John A. Lewicki Chief Scientific Officer | AGrant or award Share Options (Right to buy)derivative | +145,000 | $0.00 | $0 | 145,000 | Feb 2, 2026 |
| Feb 1, 2026 | Christine Ann Fox Chief Financial Officer | AGrant or award Share Options (Right to buy)derivative | +280,000 | $0.00 | $0 | 280,000 | Feb 2, 2026 |
| Feb 5, 2025 | Jeremy Bender director | AGrant or award Share Options (Right to buy)derivative | +55,000 | $0.00 | $0 | 55,000 | Feb 6, 2025 |
| Feb 5, 2025 | Anders Ekblom director | AGrant or award Share Options (Right to buy)derivative | +55,000 | $0.00 | $0 | 55,000 | Feb 6, 2025 |
| Feb 5, 2025 | Pierre Jacquet director | AGrant or award Share Options (Right to buy)derivative | +55,000 | $0.00 | $0 | 55,000 | Feb 6, 2025 |
| Feb 5, 2025 | Annalisa Jenkins director | AGrant or award Share Options (Right to buy)derivative | +55,000 | $0.00 | $0 | 55,000 | Feb 6, 2025 |
| Feb 5, 2025 | Jeremy Bender director | AGrant or award Deferred Restricted Stock Unitsderivative | +16,768 | - | - | 16,768 | Feb 6, 2025 |
| Feb 5, 2025 | Anders Ekblom director | AGrant or award Deferred Restricted Stock Unitsderivative | +19,054 | - | - | 19,054 | Feb 6, 2025 |
| Feb 5, 2025 | Pierre Jacquet director | AGrant or award Deferred Restricted Stock Unitsderivative | +15,243 | - | - | 15,243 | Feb 6, 2025 |
| Feb 5, 2025 | Annalisa Jenkins director | AGrant or award Deferred Restricted Stock Unitsderivative | +15,243 | - | - | 15,243 | Feb 6, 2025 |
| Jan 25, 2025 | Christine Ann Fox Chief Financial Officer | AGrant or award Share Options (Right to buy)derivative | +262,000 | $0.00 | $0 | 262,000 | Jan 28, 2025 |
| Jan 25, 2025 | Alexandra Hughes-Wilson See Remarks | AGrant or award Share Options (Right to buy)derivative | +154,000 | $0.00 | $0 | 154,000 | Jan 28, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Jeremy Benderceo, officer, director
- Anders Ekblomdirector
- Christine Ann FoxChief Financial Officer
- Alexandra Hughes-WilsonSee Remarks
- Pierre Jacquetdirector
- Annalisa Jenkinsdirector
- John A. LewickiChief Scientific Officer
- Deepika Pakianathandirector
- Denise Scots-KnightChief Executive Officer
- Charles SermonGeneral Counsel
- Daniel Shamesdirector
- Michael S Wyzgadirector
- Marc J Yoskowitzdirector
Questions about MREO
Answered from the filings on this page, as of the latest one.
Are insiders buying MREO?
No. In the last 90 days no insider at Mereo BioPharma Group plc bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade MREO on the open market?
No open-market trade has been scored at Mereo BioPharma Group plc. The latest Form 4 on file was filed on Feb 27, 2026 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at Mereo BioPharma Group plc?
13 people have filed a Form 4 at Mereo BioPharma Group plc, among them Jeremy Bender (CEO and director), Anders Ekblom (director), Christine Ann Fox (Chief Financial Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.